High-density EEG study in patients with schizophrenia treated with cariprazine

Area of Science:

• Neuroscience
• Psychiatry
• Biomarkers

Background:

• Schizophrenia presents persistent negative and cognitive symptoms, often resistant to treatment.
• Cariprazine, a dopamine D3/D2 partial agonist, shows promise for these symptoms.
• Understanding cariprazine's neurophysiological mechanisms is crucial for drug discovery and clinical use.

Purpose of the Study:

• To investigate the neurophysiological effects of cariprazine treatment in schizophrenia patients using resting-state EEG.
• To explore EEG spectral analysis as a tool for monitoring treatment response and predicting outcomes.

Main Methods:

• An open-label study involving 27 schizophrenia patients undergoing high-density resting-state EEG before and during cariprazine treatment.
• Power spectral analysis across frequency bands and cortical regions, with specific focus on gamma-activity in the dorsolateral prefrontal cortex (DLPFC), inferior frontal gyrus (IFG), and temporoparietal junction (TPJ).
• Symptom changes assessed using the Positive and Negative Syndrome Scale (PANSS).

Main Results:

• Cariprazine treatment correlated with significant symptom improvement, especially in negative and general domains.
• EEG analysis revealed increased spectral power in theta and alpha bands, consistent with preclinical findings.
• Symptom reduction was linked to increased theta and decreased delta power.
• Baseline gamma-activity in the IFG and DLPFC predicted treatment response with high accuracy (AUC 0.72-0.92).

Conclusions:

• Resting-state EEG spectral measures correlate with cariprazine treatment response in schizophrenia.
• EEG biomarkers show promise for predicting and monitoring treatment outcomes.
• Findings support the cross-species translatability of spectral measures for schizophrenia research.